Related Experiment Video
Updated: Jul 19, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
New and Delayed Artifactual Hypoglycemia Following Septic Shock in Two Scleroderma Patients
Alex Guzner1, Emil Heinze2, Lakshmi Sadasivam3
1Internal Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Abstract:
The term artifactual hypoglycemia refers to a discrepancy between plasma glucose levels and what is noted on fingerstick glucose checks. In this report, we discuss the cases of two patients with scleroderma and Raynaud's phenomenon who developed artifactual hypoglycemia while recovering from critical illness. In both cases, validation by earlobe measurements helped avoid further escalation of care and potential patient safety issues. There have been previous reports of artifactual hypoglycemia in this patient population, but the unique timing of symptom onset in these two patients provides a more nuanced understanding of the pathophysiology of this phenomenon.
More Related Videos
Related Concept Videos
Hypoglycemia and Glucagon
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Sulfonylureas

